Evofem Biosciences, Inc. (EVFM)
| Market Cap | 940.96K -20.7% |
| Revenue (ttm) | 18.05M +4.5% |
| Net Income | -15.52M |
| EPS | -0.12 |
| Shares Out | 132.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 452,766 |
| Open | 0.0077 |
| Previous Close | 0.0080 |
| Day's Range | 0.0071 - 0.0077 |
| 52-Week Range | 0.0008 - 0.0200 |
| Beta | -1.30 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
About Evofem Biosciences
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. The company’s commercial products include PHEXXI, a hormone-free contraceptive vaginal gel; and SOLOSEC, a single-dose oral antimicrobial agent for the treatment of bacterial vaginosis and trichomoniasis. Evofem Biosciences, Inc. is headquartered in San Diego, California. [Read more]
Financial Performance
Financial StatementsNews
Evofem Biosciences Quarterly report: Q2 2026
Evofem Biosciences has published its Q2 2026 quarterly earnings report on August 14, 2026.
Evofem Biosciences Earnings release: Q2 2026
Evofem Biosciences released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Evofem reports shipment of 500,000th box of PHEXX
Evofem (EVFM) Biosciences announced the shipment of its 500,000th box of PHEXX, the first and only FDA-approved hormone-free, on-demand prescription contraceptive vaginal gel.
Evofem Biosciences Slides: Investor presentation
Evofem Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on July 20, 2026.
Evofem reports Q1 EPS (4c) vs. 0c last year
Reports Q1 revenue $0.9M vs. $0.8M last year. “Evofem (EVFM) continues to execute our strategy to increase revenues and to diversify and reduce risk in our revenue stream,” said Saundra…
Evofem Reports First Quarter 2026 Financial Results and Provides Business Update
SAN DIEGO--(BUSINESS WIRE)---- $EVFM #BV--Women's health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the first quarter ended March 3...
Evofem Biosciences Quarterly report: Q1 2026
Evofem Biosciences has published its Q1 2026 quarterly earnings report on May 15, 2026.
Evofem Biosciences Earnings release: Q1 2026
Evofem Biosciences released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
Evofem enters exclusive distribution agreement with Clovis Davis for SOLOSEC
Evofem (EVFM) Biosciences entered into an exclusive Distribution Agreement with Clovis Davis Pharmaceuticals to commercialize SOLOSEC 2g oral granules in sub-Saharan Africa. SOLOSEC is approved by the...
Evofem Announces Exclusive Agreement for the Distribution and Commercialization of SOLOSEC in Sub-Saharan Africa
SAN DIEGO--(BUSINESS WIRE)---- $EVFM #BV--Women's health innovator Evofem Biosciences, Inc. (OTCID: EVFM) (Evofem or the Company) today announced that it has entered into an exclusive Distribution Agr...
Evofem Reports Fifth Consecutive Year of Net Sales Growth
SAN DIEGO--(BUSINESS WIRE)---- $EVFM #BV--Women's health pioneer Evofem reported its fifth consecutive year of top line growth, with 2025 net product sales of more than $20 million.
Evofem Biosciences Slides: Investor presentation
Evofem Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on March 11, 2026.
Evofem Biosciences Earnings release: Q4 2025
Evofem Biosciences released its Q4 2025 earnings on March 11, 2026, summarizing the period's financial results.
Evofem Biosciences Annual report: Q4 2025
Evofem Biosciences has published its Q4 2025 annual report on March 11, 2026.
Evofem CEO Saundra Pelletier Calls for a “Ground-Up Reset” of Women's Health at Fierce JPM Week 2026
SAN DIEGO--(BUSINESS WIRE)---- $EVFM #Fierce--Evofem CEO's fiery keynote address at Fierce JPM Week 2026 calls for “Ground-Up Reset” of Women's Health. Replay now live at fiercejpmweek.com.
Evofem Expands “Say Vagina” Campaign With Launch of Say Vagina Store
SAN DIEGO--(BUSINESS WIRE)---- $EVFM #sayvagina--Evofem launched SayVaginaStore.com, expanding its 'Say Vagina' campaign addressing widespread censorship of female anatomical terms in the media.
Evofem Biosciences Slides: Investor presentation
Evofem Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on January 11, 2026.
Favorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercialization in UAE
— PHEXX® Poised to Become First and Only Hormone-Free Contraceptive Vaginal Gel Approved in UAE — — 2026 Launch Planned for Hormone-Free Contraceptive in UAE — SAN DIEGO , Nov. 21, 2025 /PRNewswire/ ...
Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update
-- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter -- -- Delivered $1.0 Million of Operating Income in Q3 2025 -- SAN DIEGO , Nov. 13, 2025 /PRNewswire/ -- Women's...
Evofem Biosciences Earnings release: Q3 2025
Evofem Biosciences released its Q3 2025 earnings on November 13, 2025, summarizing the period's financial results.
Evofem Biosciences Quarterly report: Q3 2025
Evofem Biosciences has published its Q3 2025 quarterly earnings report on November 13, 2025.
Evofem Biosciences Proxy statement: Proxy Filing
Evofem Biosciences filed a proxy statement on October 29, 2025, providing details for shareholder voting and corporate governance matters.
Evofem Announces Voting Results from Special Meeting of Stockholders
-- Evofem Shareholders Did Not Approve the Merger with Aditxt -- -- Evofem Pivots to Target National Listing for Stock, Growth Capital to Catalyze Net Sales -- SAN DIEGO , Oct. 20, 2025 /PRNewswire/ -...
Evofem Biosciences Proxy statement: Proxy Filing
Evofem Biosciences filed a proxy statement on October 20, 2025, providing details for shareholder voting and corporate governance matters.
Evofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates
— First ex-U.S. Regulatory Filing for SOLSOEC® — — Pharma 1 Targets 1H 2026 Launch in UAE for SOLOSEC® to Treat Bacterial Vaginosis and Trichomoniasis, leveraging its commercial infrastructure and e...